How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
19
NVCR Quote, Financials, Valuation and Earnings
Last price:
$12.42
Seasonality move
:
5.08%
Day range:
$12.24 - $12.57
52-week range:
$10.70 - $25.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.13x
P/B ratio:
4.07x
Volume:
1.3M
Avg. volume:
1.2M
1-year change:
-51.39%
Market cap:
$1.4B
Revenue:
$605.2M
EPS (TTM):
-$1.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$170.9M | -$0.39 | 8.6% | -28% | $24.07 |
|
CATX
Perspective Therapeutics, Inc.
|
$125K | -$0.36 | -57.02% | -40.33% | $12.4167 |
|
INFU
InfuSystem Holdings, Inc.
|
$37.1M | $0.05 | 8.36% | 39.86% | $14.20 |
|
LIVN
LivaNova Plc
|
$374.6M | $1.11 | 6.94% | -20.28% | $73.00 |
|
VNRX
VolitionRX Ltd.
|
$986.3K | -$0.04 | 227.21% | -28.83% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$29.6M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$12.40 | $24.07 | $1.4B | -- | $0.00 | 0% | 2.13x |
|
CATX
Perspective Therapeutics, Inc.
|
$3.7900 | $12.4167 | $281.7M | -- | $0.00 | 0% | 256.98x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.26 | $14.20 | $168M | 31.59x | $0.00 | 0% | 1.24x |
|
LIVN
LivaNova Plc
|
$65.71 | $73.00 | $3.6B | 38.16x | $0.00 | 0% | 2.67x |
|
VNRX
VolitionRX Ltd.
|
$0.29 | $2.20 | $35M | -- | $0.00 | 0% | 19.53x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.59 | $1.50 | $82.9M | 58.04x | $0.00 | 0% | 0.65x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
70.04% | 0.578 | 55.15% | 1.44x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
LIVN
LivaNova Plc
|
29.6% | 1.670 | 17.01% | 1.05x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
NovoCure Ltd. vs. Competitors
-
Which has Higher Returns NVCR or CATX?
Perspective Therapeutics, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -12425.36%. NovoCure Ltd.'s return on equity of -50.08% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About NVCR or CATX?
NovoCure Ltd. has a consensus price target of $24.07, signalling upside risk potential of 94.12%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.4167 which suggests that it could grow by 223.22%. Given that Perspective Therapeutics, Inc. has higher upside potential than NovoCure Ltd., analysts believe Perspective Therapeutics, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 CATXPerspective Therapeutics, Inc.11 1 0 -
Is NVCR or CATX More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock NVCR or CATX?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or CATX?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. NovoCure Ltd.'s net income of -$37.3M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.13x versus 256.98x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.13x -- $167.2M -$37.3M CATXPerspective Therapeutics, Inc.256.98x -- $209K -$26M
-
Which has Higher Returns NVCR or INFU?
InfuSystem Holdings, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 6.19%. NovoCure Ltd.'s return on equity of -50.08% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About NVCR or INFU?
NovoCure Ltd. has a consensus price target of $24.07, signalling upside risk potential of 94.12%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 71.91%. Given that NovoCure Ltd. has higher upside potential than InfuSystem Holdings, Inc., analysts believe NovoCure Ltd. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is NVCR or INFU More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock NVCR or INFU?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or INFU?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. NovoCure Ltd.'s net income of -$37.3M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 31.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.13x versus 1.24x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.13x -- $167.2M -$37.3M INFUInfuSystem Holdings, Inc.1.24x 31.59x $36.5M $2.3M
-
Which has Higher Returns NVCR or LIVN?
LivaNova Plc has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 7.49%. NovoCure Ltd.'s return on equity of -50.08% beat LivaNova Plc's return on equity of -18.29%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B LIVNLivaNova Plc68.44% $0.49 $1.6B -
What do Analysts Say About NVCR or LIVN?
NovoCure Ltd. has a consensus price target of $24.07, signalling upside risk potential of 94.12%. On the other hand LivaNova Plc has an analysts' consensus of $73.00 which suggests that it could grow by 11.09%. Given that NovoCure Ltd. has higher upside potential than LivaNova Plc, analysts believe NovoCure Ltd. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 LIVNLivaNova Plc6 2 0 -
Is NVCR or LIVN More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison LivaNova Plc has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.741%.
-
Which is a Better Dividend Stock NVCR or LIVN?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LivaNova Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. LivaNova Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or LIVN?
NovoCure Ltd. quarterly revenues are $167.2M, which are smaller than LivaNova Plc quarterly revenues of $357.8M. NovoCure Ltd.'s net income of -$37.3M is lower than LivaNova Plc's net income of $26.8M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while LivaNova Plc's PE ratio is 38.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.13x versus 2.67x for LivaNova Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.13x -- $167.2M -$37.3M LIVNLivaNova Plc2.67x 38.16x $357.8M $26.8M
-
Which has Higher Returns NVCR or VNRX?
VolitionRX Ltd. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -862.39%. NovoCure Ltd.'s return on equity of -50.08% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About NVCR or VNRX?
NovoCure Ltd. has a consensus price target of $24.07, signalling upside risk potential of 94.12%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 671.93%. Given that VolitionRX Ltd. has higher upside potential than NovoCure Ltd., analysts believe VolitionRX Ltd. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 VNRXVolitionRX Ltd.4 2 0 -
Is NVCR or VNRX More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock NVCR or VNRX?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or VNRX?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. NovoCure Ltd.'s net income of -$37.3M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.13x versus 19.53x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.13x -- $167.2M -$37.3M VNRXVolitionRX Ltd.19.53x -- $627.3K -$5.4M
-
Which has Higher Returns NVCR or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 3.93%. NovoCure Ltd.'s return on equity of -50.08% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About NVCR or XTNT?
NovoCure Ltd. has a consensus price target of $24.07, signalling upside risk potential of 94.12%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 153.38%. Given that Xtant Medical Holdings, Inc. has higher upside potential than NovoCure Ltd., analysts believe Xtant Medical Holdings, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is NVCR or XTNT More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock NVCR or XTNT?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or XTNT?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. NovoCure Ltd.'s net income of -$37.3M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 58.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.13x versus 0.65x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.13x -- $167.2M -$37.3M XTNTXtant Medical Holdings, Inc.0.65x 58.04x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
